Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages i171-i181

  McGregor, Julie Anne G ^a   Negrete Lopez, Roberto ^b   Poulton, Caroline J ^a   Kidd, Jason M ^c   Katsanos, Suzanne L ^a   Goetz, Lindsey ^d   Hu, Yichun ^a   Nachman, Patrick H ^a   Falk, Ronald J ^a   Hogan, Susan L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

ANCA; glomerulonephritis; immunosuppression; outcomes; risk factors

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; PEROXIDASE;

ADULT; ANCA ASSOCIATED VASCULITIS; ANTIBODY SPECIFICITY; ARTICLE; CELLULITIS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; END STAGE RENAL DISEASE; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; INFECTION; KIDNEY FUNCTION; LEUKOPENIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; OTITIS MEDIA; PATHOGEN LOAD; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RISK ASSESSMENT; SEX DIFFERENCE; STAPHYLOCOCCUS AUREUS; THRUSH; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; KIDNEY; LONGITUDINAL STUDY; MICROBIOLOGY; PHYSIOLOGY; PROGNOSIS; STAPHYLOCOCCAL INFECTIONS; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NORTH CAROLINA; PEROXIDASE; PROGNOSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE;

EID: 84926618081     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv045     Document Type: Article

References (33)

1. Zeek PM. Periarteritis nodosa and other forms of necrotizing angiitis. N Engl J Med 1953; 248: 764-772
2. Rose GA, Spencer H. Polyarteritis nodosa. Q J Med 1957; 26: 43-81
3. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43: 8-14
4. Fauci AS, Haynes BF, Katz P et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
5. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317
6. Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis [see comments]. Arthritis Rheum 1997; 40: 2187-2198
7. Hoffman GS, Leavitt RY, Fleisher TA et al. Treatment of Wegener's granu-lomatosis with intermittent high-dose intravenous cyclophosphamide [see comments]. Am J Med 1990; 89: 403-410
8. de Groot K, Harper L, Jayne DR et al. Pulse versus daily oral cyclophos-phamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-680
9. Nachman PH, Hogan SL, Jennette JC et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-39
10. Little MA, Nightingale P, Verburgh CA et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 1036-1043
11. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
12. Specks U, Merkel PA, Seo P et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-427
13. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophospha-mide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
14. Hogan J, Avasare R, Radhakrishnan J. Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol 2014; 9: 1657-1667
15. Hogan SL, Nachman PH, Wilkman AS et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32
16. Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol 2010; 21: 745-752
17. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculit-ides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
18. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006; 55: 146-149
19. Allenbach Y, Seror R, Pagnoux C et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulo-matosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68: 564-567
20. Merkel PA, Lo GH, Holbrook JT et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulo-matosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142: 620-626
21. Stassen PM, Derks RP, Kallenberg CG et al. Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors. Rheumatology (Oxford) 2008; 47: 530-534
22. Levey AS, Coresh J, Greene T et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772
23. Wall N, Harper L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol 2012; 8: 523-532
24. Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-1032
25. Lai QY, Ma TT, Li ZY et al. Predictors for mortality in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients. J Rheumatol 2014; 41: 1849-1855
26. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients [see comments]. Ann Intern Med 1992; 116: 488-498
27. Flossmann O, Berden A, de GK et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488-494
28. Stegeman CA, Cohen Tervaert JW, Manson WL et al. Chronic nasal carriage of Staphylococcal aureus in Wegener's granulomatosis identifies a subgroup of patients more prone to relapse. Ann Intern Med 1994; 120: 12-17
29. McGregor JG, Hogan SL, Hu Y et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012; 7: 240-247
30. Lightstone L. Minimising steroids in lupus nephritis-will B cell depletion pave the way? Lupus 2013; 22: 390-399
31. Tadema H, Abdulahad WH, Lepse N et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford) 2011; 50: 689-696
32. Tadema H, Abdulahad WH, Stegeman CA et al. Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-asso-ciated vasculitis. PLoS One 2011; 6: e24315
33. Kallenberg CG, Stegeman CA, Abdulahad WH et al. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. Am J Kidney Dis 2013; 62: 1176-1187